Biotechnology company focused on developing therapies for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.
Akero Therapeutics, Inc. is a biopharmaceutical company focused on addressing cardio-metabolic conditions, particularly nonalcoholic steatohepatitis (NASH), through the development of innovative medicines aimed at restoring metabolic balance and enhancing overall health. At the forefront of its pipeline is efruxifermin (EFX), a promising analog of fibroblast growth factor 21 (FGF21). EFX is designed to mitigate cellular stress and regulate the metabolism of lipids, carbohydrates, and proteins throughout the body.
Currently, Akero Therapeutics is advancing EFX through a Phase 2a clinical trial known as the BALANCED study. This trial aims to evaluate the efficacy of EFX specifically in patients with biopsy-confirmed NASH, positioning the company at the forefront of therapeutic advancements in this challenging metabolic disorder.
Founded in 2017 and originally named Pippin Pharmaceuticals, Inc., Akero Therapeutics rebranded in May 2018 to reflect its strategic focus and commitment to addressing significant unmet medical needs in metabolic diseases. Headquartered in South San Francisco, California, the company leverages innovative research and development strategies to pioneer new treatments that could potentially transform the management of NASH and related conditions.
Akero Therapeutics operates with a mission to develop therapies that not only target the underlying mechanisms of metabolic disorders but also improve the overall health outcomes of patients worldwide. With its cutting-edge approach and dedicated team, the company aims to make meaningful contributions to the field of cardio-metabolic health.